Nurix Therapeutics (NRIX) Capital Expenditures (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Capital Expenditures data on file, last reported at $1.3 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 153.27% year-over-year to $1.3 million in Q2 2026; TTM through May 2026 was $3.1 million, a 288.65% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, down 28.0% from the prior year.
• Capital Expenditures for Q2 2026 stood at $1.3 million, down from $1.7 million in the prior quarter.
• Over the last five years, Capital Expenditures for NRIX reached as high as $7.0 million in Q3 2022 and fell as low as -$5.5 million in Q4 2024.
• Historically, Capital Expenditures has averaged $1.0 million across 5 years, with a median of $1.2 million in 2023.
• Across the five-year window, Capital Expenditures surged 311.86% in 2022 and sank 323.12% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $2.6 million in 2022, then slumped by 302.11% to -$5.2 million in 2023, then slipped by 6.58% to -$5.5 million in 2024, then surged by 83.04% to -$937000.0 in 2025, then soared by 236.61% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $1.3 million in Q2 2026, $1.7 million in Q1 2026, and -$937000.0 in Q4 2025.